ProSemble Ltd
ProSemble is a King's College laboratory-based start-up. Dr Julien Bergeron (ProSemble’s CEO/CSO and a senior lecturer in biophysics/biomedicine and the leader of the Bergeron Laboratory at King’s College ) has discovered a protein that binds medicine disbursed during later stages of cancer treatment (particularly, in breast cancers) that takes the medicine directly to the tumour for its release to be triggered with a specific chemical reaction. ProSemble biotech and AI innovation does not deal with new anti-cancer drugs but with a way currently prescribed medicine, such as Doxorubicin, is administered, which minimises or even eliminates side effects.
ProSemble is a B2B company that will sell or license its modifications and supporting AI to pharma. The IP has been filed in the USA by King’s College (that is taking a stake in the company in lieu of contributing the IP back to ProSemble). The AI module has already been coded in Python by Marek Oleksiewicz, ProSemble’s CTO, and is currently being fine-tuned. ProSemble has started initial talks with pharma (Takeda, AstraZeneca) and will progress to LOIs upon completing the requested experiments re results in tox assay in mice.
ProSemble’s initial focus is on breast cancer and Doxorubicin. Once the breast cancer market is covered (a multi-billion-dollar industry) the same tech (with some relatively simple adjustments) can be applied to other cancers and diseases where targeted delivery of medicine is paramount. We will then also look at acquiring rights to drugs that failed clinical trials as believe our biotech and AI know-how can be a difference between them failing or passing clinical trials.
ProSemble is looking to raise $400,000 to employ two full-time research assistants to complete the research requested by Takeda and other pharma, procure necessary reagents, fine-tune the AI and expand business development/sales activities with pharma, which will be initially undertaken by Julien Bergeron and Inna Zhuranskaya (CFO/Head of Business Development).